These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20085389)

  • 1. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
    Stafinski T; McCabe CJ; Menon D
    Pharmacoeconomics; 2010; 28(2):113-42. PubMed ID: 20085389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access with evidence development schemes: a framework for description and evaluation.
    McCabe CJ; Stafinski T; Edlin R; Menon D;
    Pharmacoeconomics; 2010; 28(2):143-52. PubMed ID: 20085390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access with evidence development in the UK: past experience, current initiatives and future potential.
    Briggs A; Ritchie K; Fenwick E; Chalkidou K; Littlejohns P
    Pharmacoeconomics; 2010; 28(2):163-70. PubMed ID: 20085392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access with evidence development: the US experience.
    Mohr PE; Tunis SR
    Pharmacoeconomics; 2010; 28(2):153-62. PubMed ID: 20085391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
    Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
    Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To fund or not to fund: development of a decision-making framework for the coverage of new health technologies.
    Stafinski T; Menon D; McCabe C; Philippon DJ
    Pharmacoeconomics; 2011 Sep; 29(9):771-80. PubMed ID: 21756008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Access to High-Cost Technologies in the Asia Region.
    Mundy L; Trowman R; Kearney B
    Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.
    Kolasa K; Kalo Z; Hornby E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):145-55. PubMed ID: 24964864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the added value of health technologies: reconciling different perspectives.
    Drummond M; Tarricone R; Torbica A
    Value Health; 2013; 16(1 Suppl):S7-13. PubMed ID: 23317646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.
    Walker S; Sculpher M; Claxton K; Palmer S
    Value Health; 2012 May; 15(3):570-9. PubMed ID: 22583469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
    Lee SS; Salole E
    Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology funding decision-making processes around the world: the same, yet different.
    Stafinski T; Menon D; Philippon DJ; McCabe C
    Pharmacoeconomics; 2011 Jun; 29(6):475-95. PubMed ID: 21568357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Medical Care Program for the Rapid Introduction of Healthcare Technologies to the National Health Insurance System in Japan.
    Ueda K; Sanada S; Uemura N
    Clin Transl Sci; 2020 Jul; 13(4):700-706. PubMed ID: 32004408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.